Jubilant Pharmova Limited

BSE: 530019 NSE: JUBLPHARMA
Jubilant Pharmova Limited - pharma in U P, Uttar Pradesh, India. FY 2026 financials and compliance.
CIN L24116UP1978PLC004624 Incorporated 21 June 1978 ROC Kanpur HQ U P, Uttar Pradesh, India
Active Listed - NSE: JUBLPHARMA · BSE: 530019 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹8,279.6 Cr
▲ 14.45% YoY
EBITDA · FY 2026
₹1,325.8 Cr
▲ 7.74% YoY
Net profit · FY 2026
₹397.5 Cr
▼ 52.47% YoY
Authorised capital
₹143.02 Cr
Registered with MCA
Paid-up capital
₹15.93 Cr
Issued & subscribed
Open charges
₹360 Cr
Satisfied ₹9,185.57 Cr
Company age
48 yrs
Est. 1978
Employees · EPFO
1,055
Latest available

About Jubilant Pharmova Limited

Data last updated: 23 December 2025

Jubilant Pharmova Limited is a public limited company based in U P, Uttar Pradesh, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 21 June 1978, the company has been in operation for over 48 years.

Registered with ROC Kanpur under CIN L24116UP1978PLC004624. Listed on BSE: 530019 and NSE: JUBLPHARMA.

Capital: an authorised share capital of ₹143.02 Cr and a paid-up capital of ₹15.93 Cr. Formerly known as Vam Organic Chemicals Limited and Jubilant Organosys Limited. It is led by directors including Arvind Chokhany and Shyam Sunder Bhartia.

Last AGM: 29 August 2025. Financial statements filed for year ended 31 March 2025. Office: Bhartiagram Gajraulajyotiba Phoolay Nagar, U P, Uttar Pradesh, India – 244223.

As per the financials filed for FY 2025, the company reported a revenue of ₹7,291.3 Cr, a growth of 8% compared to the previous year.

The company has a workforce of approximately 1,055 employees as per the latest available data. Its group structure includes 7 subsidiaries.

The company is associated with 3 brands - Jubilant Biosys, Jubilant Life Sciences, Jubilant Pharmova. As per MCA filings, the company has open charges of ₹360 Cr and satisfied charges of ₹9,185.57 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jubilantpharmova.com.

Company Details of Jubilant Pharmova Limited
CIN L24116UP1978PLC004624
Registration Number 004624
Incorporation Date 21 June 1978
ROC Kanpur
Listing Status Listed (BSE: 530019, NSE: JUBLPHARMA)
Company Status Active
Date of Last AGM 29 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Arjun Shanker Bhartia Managing Director Priyavrat Bhartia Managing Director Arvind Chokhany Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    jubilantpharmova.com
  • Social Media
  • Registered Address
    Bhartiagram Gajraulajyotiba Phoolay Nagar, U P, Uttar Pradesh, India – 244223
  • Industry
    Pharma, API Manufacturers
Company report
Jubilant Pharmova Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Jubilant Pharmova Limited report

Financials, compliance, directors, charges, ownership and filings for Jubilant Pharmova Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Jubilant Pharmova Limited

Jubilant Pharmova Limited has undergone 3 name changes throughout its history. The company was previously known as Vam Organic Chemicals Limited, Jubilant Organosys Limited, and Jubilant Life Sciences Limited. The current legal name is Jubilant Pharmova Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Jubilant Pharmova Limited Current
Vam Organic Chemicals Limited Previous
Jubilant Organosys Limited Previous
Jubilant Life Sciences Limited Previous

CIN History of Jubilant Pharmova Limited

Jubilant Pharmova Limited has one previous CIN (Corporate Identification Number): U24116UP1978PLC004624. The current CIN is L24116UP1978PLC004624, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24116UP1978PLC004624 Current
U24116UP1978PLC004624 Previous

Associated Brands with Jubilant Pharmova Limited

Jubilant Pharmova Limited operates multiple associated brands including Jubilant Biosys, Jubilant Life Sciences, and Jubilant Pharmova. These brands represent Jubilant Pharmova Limited's diversified market presence and brand portfolio.

Brand Description Website
Jubilant Biosys
Offers integrated drug discovery, research, and manufacturing for pharmaceuticals. jubilantbiosys.com
Jubilant Life Sciences
Company offering a suite of R&D and manufacturing services for small molecules and generics jubl.com
Jubilant Pharmova
CDMO focused on manufacturing of solid, semi solid, liquid, and injectible drug formulations jubilantpharmova.com

Competitors & Alternatives of Jubilant Pharmova Limited

Brands and companies operating in the same space as Jubilant Pharmova Limited include Evotec, Akums, Crown Bioscience and 7 more.

Competitor Description Location Founded
Evotec Evotec Drug discovery and development services are provided to biopharma sector. Hamburg, Germany, Germany 1993
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segments Delhi, India, India 2004
Crown Bioscience Crown Bioscience Cancer and CVMD drugs are developed using PDX models. Santa Clara, United States, United States 2006
NIH NIH Drug discovery services are provided to the biopharma sector. United States 1887
Domainex Domainex Drug discovery CRO company for epigenetic research and inflammatory diseases Cambridge, United Kingdom, United Kingdom 2001
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured. Chandigarh, India, India 1995
Windlas Windlas Biopharma regulatory affairs, quality control, and strategy services are provided. Gurugram, India, India 2001
Unither Unither Contract development and manufacturing organization for proprietary and generic drugs Paris, France, France 1993
Alloy Therapeutics Alloy Therapeutics Drug discovery services are provided for therapeutic development. Lexington, United States, United States 2017
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually. Jordbro, Sweden, Sweden 1995

Business Activity of Jubilant Pharmova Limited

Jubilant Pharmova Limited is engaged in principal business activities including professional, scientific and technical and manufacturing, with detailed activities including management consultancy activities, chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
M Professional, Scientific and Technical M3 Management consultancy activities *********
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Jubilant Pharmova Limited

Jubilant Pharmova Limited is audited by Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Jubilant Pharmova Limited

Jubilant Pharmova Limited is currently managed by 13 directors, with 41 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Arvind Chokhany
Also directs: Jubilant Biosys Limited
Whole-Time Director 01 Apr 2021 5 Years 3 Months Current
Shyam Sunder Bhartia
Also directs: Spb Management Advisors Llp, Ssbsb Advisors Llp, Sbssb Advisors Llp and 5 more
Director 21 Jun 1978 48 Years 0 Months Current
Hari Shanker Bhartia
Also directs: Jubilant Ingrevia Limited, Jubilant Foodworks Limited, Jubilant Enpro Private Limited and 5 more
Director 01 Nov 1983 42 Years 8 Months Current
Arun Kumar Sharma
Also directs: Jubilant Clinsys Limited, Jubilant First Trust Healthcare Limited, Jubilant Draximage Limited and 1 more
Cfo 01 Oct 2025 0 Years 9 Months Current
Shivpriya Nanda
Also directs: Baxy Limited, Greenpanel Industries Limited
Director 01 Apr 2024 2 Years 3 Months Current
Shirish Gundopant Belapure
Also directs: Bellapure Onco Phytoceuticals Llp, Corona Remedies Limited, Innova Captab Limited and 3 more
Director 07 Mar 2023 3 Years 4 Months Current
Showing 6 of 13 current directors. View all directors

Financials of Jubilant Pharmova Limited FY 2026 filings available

Jubilant Pharmova Limited reported revenue of ₹8,279.6 Cr (up 14.45% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹8,279.6 Cr ▲ 14.45%
Profit · FY 2026
₹397.5 Cr ▼ 52.47%
EBITDA · FY 2026
₹1,325.8 Cr ▲ 7.74%
Revenue₹ Cr · Consolidated05,00010,000FY 2020: ₹9,154 Cr9,154FY 2020FY 2022: ₹6,059 Cr · -33.8% YoY6,059-33.8%FY 2022FY 2023: ₹6,282 Cr · +3.7% YoY6,282+3.7%FY 2023FY 2024: ₹670 Cr · -89.3% YoY670-89.3%FY 2024FY 2025: ₹7,235 Cr · +979.3% YoY7,234+979.3%FY 2025FY 2026: ₹8,280 Cr · +14.4% YoY8,280+14.4%FY 2026
Net Profit₹ Cr · Consolidated-50005001,000FY 2020: ₹898 Cr898FY 2020FY 2022: ₹413 Cr · -54% YoY413-54%FY 2022FY 2023: ₹65 Cr (loss) · -115.7% YoY-64.9FY 2023FY 2024: ₹7 Cr · +111.2% YoY7.3+111.2%FY 2024FY 2025: ₹836 Cr · +11403.4% YoY836+11403.4%FY 2025FY 2026: ₹398 Cr · -52.5% YoY398-52.5%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year01,0002,0003,000Q1'25: ₹1,732 Cr · +9.1% YoY1,732+9.1%Q1'25Q2'25: ₹1,752 Cr · +4.3% YoY1,752+4.3%Q2'25Q3'25: ₹1,822 Cr · +8.6% YoY1,822+8.6%Q3'25Q4'25: ₹1,929 Cr · +996.8% YoY1,929+996.8%Q4'25Q1'26: ₹1,901 Cr · +9.8% YoY1,901+9.8%Q1'26Q2'26: ₹1,966 Cr · +12.2% YoY1,966+12.2%Q2'26Q3'26: ₹2,123 Cr · +16.5% YoY2,122+16.5%Q3'26Q4'26: ₹2,290 Cr · +18.7% YoY2,290+18.7%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2020
Revenue from Operations ₹8,279.6 Cr ₹7,234.5 Cr ₹670.29 Cr ₹6,281.73 Cr ₹6,059.17 Cr ₹9,154.41 Cr
Other Income ₹66 Cr ₹56.8 Cr ₹6.87 Cr ₹38.33 Cr ₹82.28 Cr ₹47.43 Cr
Total Income ₹8,345.6 Cr ₹7,291.3 Cr ₹677.16 Cr ₹6,320.06 Cr ₹6,141.45 Cr ₹9,201.84 Cr
Cost of Materials Consumed ₹2,320.3 Cr ₹1,985.3 Cr ₹182.13 Cr ₹1,666.41 Cr ₹1,348.7 Cr ₹3,119.42 Cr
Purchases of Stock-in-Trade ₹313.1 Cr ₹297.1 Cr ₹24.12 Cr ₹252.22 Cr ₹201.62 Cr ₹276.58 Cr
Changes in Inventories ₹10.9 Cr ₹34.6 Cr ₹7.82 Cr -₹40.7 Cr -₹62.32 Cr -₹255.43 Cr
Employee Benefit Expense ₹2,700.6 Cr ₹2,267.9 Cr ₹221.6 Cr ₹2,166.02 Cr ₹2,043.39 Cr ₹2,127.68 Cr
Finance Costs ₹211.8 Cr ₹240.3 Cr ₹27.23 Cr ₹188.2 Cr ₹145.49 Cr ₹287.41 Cr
Depreciation & Amortisation ₹440.4 Cr ₹368.6 Cr ₹38.19 Cr ₹554.03 Cr ₹381.7 Cr ₹461.93 Cr
Other Expenses ₹1,674.9 Cr ₹1,475.9 Cr ₹144.54 Cr ₹1,461.53 Cr ₹1,442.44 Cr ₹1,939.08 Cr
Total Expenses ₹7,672 Cr ₹6,669.7 Cr ₹645.63 Cr ₹6,247.71 Cr ₹5,501.02 Cr ₹7,956.67 Cr
Profit Before Exceptional Items & Tax ₹673.6 Cr ₹621.6 Cr ₹31.53 Cr ₹72.35 Cr ₹640.43 Cr ₹1,245.17 Cr
Exceptional Items -₹59.2 Cr ₹359.5 Cr -₹16.89 Cr -₹56.82 Cr ₹0 -₹34.64 Cr
Profit Before Tax ₹614.4 Cr ₹981.1 Cr ₹14.64 Cr ₹15.53 Cr ₹640.43 Cr ₹1,210.53 Cr
Total Tax Expense ₹216.6 Cr ₹144.3 Cr ₹9.78 Cr ₹92.66 Cr ₹217.43 Cr ₹312.29 Cr
Net Profit ₹397.5 Cr ₹836.3 Cr ₹7.27 Cr -₹64.88 Cr ₹413.02 Cr ₹898.24 Cr
  attributable to Owners ₹398.5 Cr ₹839.4 Cr ₹7.71 Cr -₹60.98 Cr ₹413.94 Cr ₹898.24 Cr
  attributable to NCI -₹1 Cr -₹3.1 Cr -₹44 Lakh -₹3.9 Cr -₹92 Lakh -
Other Comprehensive Income ₹545.8 Cr ₹85 Cr ₹5.44 Cr ₹220.43 Cr ₹243.96 Cr ₹33.11 Cr
Total Comprehensive Income ₹943.3 Cr ₹921.3 Cr ₹12.71 Cr ₹155.55 Cr ₹656.98 Cr ₹931.35 Cr
EBITDA (computed) ₹1,325.8 Cr ₹1,230.5 Cr ₹96.95 Cr ₹814.58 Cr ₹1,167.62 Cr ₹1,994.51 Cr
Basic EPS ₹25.15 ₹52.99 ₹4.87 ₹-3.83 ₹26.00 ₹56.39
Diluted EPS ₹25.08 ₹52.85 ₹4.86 ₹-3.83 ₹26.00 ₹56.39
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹15,523 Cr ₹12,756 Cr ₹1,154.85 Cr ₹11,157 Cr
Non-current Assets ₹11,413 Cr ₹9,179.2 Cr ₹767.24 Cr ₹7,394.25 Cr
Current Assets ₹4,109.3 Cr ₹3,509.7 Cr ₹363.22 Cr ₹3,762.4 Cr
Property, Plant & Equipment ₹3,509.6 Cr ₹2,132.3 Cr ₹215.78 Cr ₹2,297.53 Cr
Inventories ₹1,231.5 Cr ₹1,129.2 Cr ₹128.96 Cr ₹1,380.53 Cr
Trade Receivables ₹1,069.6 Cr ₹891.5 Cr ₹91.59 Cr ₹961.24 Cr
Cash & Equivalents ₹1,267.1 Cr ₹1,088.3 Cr ₹95.64 Cr ₹1,013.92 Cr
Equity (Net Worth) ₹7,095.6 Cr ₹6,238.6 Cr ₹542.11 Cr ₹5,391.79 Cr
Equity Share Capital ₹15.8 Cr ₹15.8 Cr ₹1.58 Cr ₹15.91 Cr
Borrowings (Non-current) ₹2,971.7 Cr ₹2,150.3 Cr ₹316.71 Cr ₹3,110.36 Cr
Borrowings (Current) ₹247.8 Cr ₹286.6 Cr ₹24.7 Cr ₹299.72 Cr
Total Debt (computed) ₹3,219.5 Cr ₹2,436.9 Cr ₹341.41 Cr ₹3,410.08 Cr
Current Liabilities ₹2,538.9 Cr ₹2,164.6 Cr ₹188.9 Cr ₹1,772.4 Cr
Total Liabilities ₹8,427.1 Cr ₹6,517.8 Cr ₹612.74 Cr ₹5,764.86 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,226.8 Cr ₹1,072.1 Cr ₹97.13 Cr ₹660.67 Cr ₹837.54 Cr
Investing Cash Flow -₹1,260 Cr ₹487.7 Cr -₹60.79 Cr -₹544.41 Cr -₹380.37 Cr
Financing Cash Flow ₹94.9 Cr -₹1,452.7 Cr -₹43.25 Cr -₹156.69 Cr -₹32.6 Cr
Capital Expenditure ₹1,449.1 Cr ₹1,115.6 Cr ₹89.77 Cr ₹814.45 Cr ₹599.99 Cr
Free Cash Flow (computed) -₹222.3 Cr -₹43.5 Cr ₹7.36 Cr -₹153.78 Cr ₹237.55 Cr
Dividends Paid ₹79.5 Cr ₹79.6 Cr ₹7.98 Cr ₹80.06 Cr ₹80.05 Cr
Net Change in Cash ₹178.8 Cr ₹131.9 Cr -₹5.75 Cr ₹30.1 Cr ₹481.86 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹2,290 Cr ₹2,122.5 Cr ₹1,966.4 Cr ₹1,900.7 Cr ₹1,928.8 Cr ₹1,821.7 Cr ₹1,752.3 Cr ₹1,731.7 Cr ₹175.86 Cr ₹1,677.1 Cr ₹1,680.3 Cr ₹1,586.9 Cr
Other Income ₹23.7 Cr ₹20.5 Cr ₹9.8 Cr ₹12 Cr ₹11.9 Cr ₹9.2 Cr ₹21.7 Cr ₹14 Cr ₹1.44 Cr ₹35.8 Cr ₹9.9 Cr ₹8.6 Cr
Total Income ₹2,313.7 Cr ₹2,143 Cr ₹1,976.2 Cr ₹1,912.7 Cr ₹1,940.7 Cr ₹1,830.9 Cr ₹1,774 Cr ₹1,745.7 Cr ₹177.3 Cr ₹1,712.9 Cr ₹1,690.2 Cr ₹1,595.5 Cr
Cost of Materials Consumed ₹642.8 Cr ₹592.1 Cr ₹564.9 Cr ₹520.5 Cr ₹584 Cr ₹467 Cr ₹469 Cr ₹465.3 Cr ₹49.73 Cr ₹431.5 Cr ₹464.4 Cr ₹428.1 Cr
Purchases of Stock-in-Trade ₹84.5 Cr ₹82 Cr ₹73.6 Cr ₹73 Cr ₹84.8 Cr ₹81.2 Cr ₹69.3 Cr ₹61.8 Cr ₹5.39 Cr ₹71.8 Cr ₹58.4 Cr ₹57.1 Cr
Changes in Inventories -₹14 Cr ₹42.2 Cr -₹42 Cr ₹24.7 Cr -₹42.7 Cr ₹26.2 Cr ₹16.5 Cr ₹34.6 Cr -₹2.38 Cr ₹32.6 Cr ₹34.5 Cr ₹34.9 Cr
Employee Benefit Expense ₹766.9 Cr ₹706.4 Cr ₹636.2 Cr ₹591.1 Cr ₹590.6 Cr ₹560.1 Cr ₹564.3 Cr ₹552.9 Cr ₹55.5 Cr ₹581.5 Cr ₹531.8 Cr ₹547.7 Cr
Finance Costs ₹56.5 Cr ₹56.1 Cr ₹50.2 Cr ₹49 Cr ₹52.7 Cr ₹55.6 Cr ₹61 Cr ₹71 Cr ₹7.3 Cr ₹71.3 Cr ₹66.1 Cr ₹61.9 Cr
Depreciation & Amortisation ₹116.8 Cr ₹120.7 Cr ₹104.8 Cr ₹98.1 Cr ₹95.2 Cr ₹91.3 Cr ₹91.4 Cr ₹90.7 Cr ₹10.1 Cr ₹94.6 Cr ₹96.6 Cr ₹89.7 Cr
Other Expenses ₹470.5 Cr ₹410.3 Cr ₹392.3 Cr ₹401.8 Cr ₹366.7 Cr ₹399.8 Cr ₹343.8 Cr ₹365.6 Cr ₹40.48 Cr ₹341.7 Cr ₹349.4 Cr ₹349.5 Cr
Total Expenses ₹2,124 Cr ₹2,009.8 Cr ₹1,780 Cr ₹1,758.2 Cr ₹1,731.3 Cr ₹1,681.2 Cr ₹1,615.3 Cr ₹1,641.9 Cr ₹166.12 Cr ₹1,625 Cr ₹1,601.2 Cr ₹1,568.9 Cr
Profit Before Exceptional Items & Tax ₹189.7 Cr ₹133.2 Cr ₹196.2 Cr ₹154.5 Cr ₹209.4 Cr ₹149.7 Cr ₹158.7 Cr ₹103.8 Cr ₹11.18 Cr ₹87.9 Cr ₹89 Cr ₹26.6 Cr
Exceptional Items -₹13.7 Cr -₹39.7 Cr -₹5.8 Cr ₹0 -₹3.3 Cr -₹18.9 Cr -₹14.2 Cr ₹395.9 Cr -₹16.89 Cr ₹0 ₹0 ₹0
Profit Before Tax ₹176 Cr ₹93.5 Cr ₹190.4 Cr ₹154.5 Cr ₹206.1 Cr ₹130.8 Cr ₹144.5 Cr ₹499.7 Cr -₹5.71 Cr ₹87.9 Cr ₹89 Cr ₹26.6 Cr
Total Tax Expense ₹56.7 Cr ₹37.6 Cr ₹70.4 Cr ₹51.9 Cr ₹54.7 Cr ₹29.8 Cr ₹41.9 Cr ₹17.9 Cr ₹81 Lakh ₹34.6 Cr ₹35.9 Cr ₹19.2 Cr
Net Profit ₹119.3 Cr ₹55.8 Cr ₹119.9 Cr ₹102.5 Cr ₹151.3 Cr ₹100.7 Cr ₹102.5 Cr ₹481.8 Cr -₹6.18 Cr ₹66.4 Cr ₹62.1 Cr ₹6 Cr
  attributable to Owners ₹119.4 Cr ₹55.9 Cr ₹120.3 Cr ₹102.9 Cr ₹153.6 Cr ₹100.9 Cr ₹102.8 Cr ₹482.1 Cr -₹5.86 Cr ₹66.8 Cr ₹62.5 Cr ₹6.4 Cr
  attributable to NCI -₹10 Lakh -₹10 Lakh -₹40 Lakh -₹40 Lakh -₹2.3 Cr -₹20 Lakh -₹30 Lakh -₹30 Lakh -₹32 Lakh -₹40 Lakh -₹40 Lakh -₹40 Lakh
Other Comprehensive Income ₹281.9 Cr ₹62.4 Cr ₹160.4 Cr ₹41.1 Cr -₹4.6 Cr ₹63.5 Cr ₹30 Cr -₹3.9 Cr -₹66 Lakh ₹17 Cr ₹34.2 Cr ₹9.8 Cr
Total Comprehensive Income ₹401.2 Cr ₹118.2 Cr ₹280.3 Cr ₹143.6 Cr ₹146.7 Cr ₹164.2 Cr ₹132.5 Cr ₹477.9 Cr -₹6.84 Cr ₹83.4 Cr ₹96.3 Cr ₹15.8 Cr
EBITDA (computed) ₹363 Cr ₹310 Cr ₹351.2 Cr ₹301.6 Cr ₹357.3 Cr ₹296.6 Cr ₹311.1 Cr ₹265.5 Cr ₹28.58 Cr ₹253.8 Cr ₹251.7 Cr ₹178.2 Cr
Basic EPS ₹7.55 ₹3.52 ₹7.59 ₹6.49 ₹9.71 ₹6.37 ₹6.47 ₹30.44 ₹-3.69 ₹4.22 ₹3.94 ₹0.40
Diluted EPS ₹7.52 ₹3.52 ₹7.57 ₹6.47 ₹9.68 ₹6.36 ₹6.46 ₹30.35 ₹-3.68 ₹4.20 ₹3.94 ₹0.40
Latest 12 quarters shown of 24 on record.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Radiopharma ₹990 Cr ₹77.8 Cr ₹3,679.2 Cr ₹1,239.4 Cr
Allergy Immunotherapy ₹217.6 Cr ₹89.8 Cr ₹631 Cr ₹131 Cr
Contract Development and Manufacturing Organisation - Sterile Injectables ₹546.5 Cr ₹55.9 Cr ₹6,058.3 Cr ₹2,785.2 Cr
Contract Research, Development and Manufacturing Organisation ₹334.8 Cr ₹36 Cr ₹1,772.7 Cr ₹441.7 Cr
Generics ₹214.4 Cr ₹17.4 Cr ₹1,241.9 Cr ₹259.4 Cr
Proprietary Novel Drugs ₹0 -₹7.4 Cr ₹330.8 Cr ₹9.8 Cr
Unallocable corporate ₹14.8 Cr ₹0 ₹1,808.8 Cr ₹3,560.6 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Radiopharma ₹3,690.1 Cr ₹359.9 Cr - -
Allergy Immunotherapy ₹795.7 Cr ₹271.7 Cr - -
Contract Development and Manufacturing Organisation - Sterile Injectables ₹1,812.6 Cr ₹206.3 Cr - -
Contract Research, Development and Manufacturing Organisation ₹1,264.9 Cr ₹123.8 Cr - -
Generics ₹773.5 Cr ₹27.6 Cr - -
Proprietary Novel Drugs ₹0 -₹19.4 Cr - -
Unallocable corporate ₹58.5 Cr ₹0 - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹263.5 Cr ₹745.7 Cr ₹784.7 Cr ₹810.12 Cr ₹87.75 Cr ₹2,709.5 Cr ₹3,139.9 Cr
Other Income ₹2.4 Cr ₹99.6 Cr ₹103.4 Cr ₹137.89 Cr ₹125.87 Cr ₹47.88 Cr ₹173.23 Cr
Total Income ₹265.9 Cr ₹845.3 Cr ₹888.1 Cr ₹948.01 Cr ₹213.62 Cr ₹2,757.38 Cr ₹3,313.13 Cr
Cost of Materials Consumed ₹0 ₹282.5 Cr ₹310 Cr ₹396.3 Cr ₹0 ₹1,328.92 Cr ₹1,683.29 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹6.5 Cr ₹14.81 Cr ₹0 ₹66.23 Cr ₹109.46 Cr
Changes in Inventories ₹0 -₹6.7 Cr ₹39 Cr ₹3.45 Cr ₹0 ₹55.21 Cr -₹108.32 Cr
Employee Benefit Expense ₹103.8 Cr ₹203 Cr ₹190 Cr ₹167.27 Cr ₹49.21 Cr ₹220.67 Cr ₹264.9 Cr
Finance Costs ₹7.3 Cr ₹29.8 Cr ₹29.9 Cr ₹18.52 Cr ₹30.59 Cr ₹101.8 Cr ₹136.2 Cr
Depreciation & Amortisation ₹6 Cr ₹53.1 Cr ₹48.3 Cr ₹43.25 Cr ₹6.25 Cr ₹99.97 Cr ₹107.4 Cr
Other Expenses ₹110.9 Cr ₹234.8 Cr ₹222.7 Cr ₹225.07 Cr ₹45.32 Cr ₹611.41 Cr ₹819.66 Cr
Total Expenses ₹228 Cr ₹796.5 Cr ₹846.4 Cr ₹868.67 Cr ₹131.37 Cr ₹2,484.21 Cr ₹3,012.59 Cr
Profit Before Exceptional Items & Tax ₹37.9 Cr ₹48.8 Cr ₹41.7 Cr ₹79.34 Cr ₹82.25 Cr ₹273.17 Cr ₹300.54 Cr
Exceptional Items -₹8.7 Cr -₹11.2 Cr ₹0 ₹0 ₹0 ₹0 -₹1.7 Cr
Profit Before Tax ₹29.2 Cr ₹37.6 Cr ₹41.7 Cr ₹79.34 Cr ₹82.25 Cr ₹273.17 Cr ₹298.84 Cr
Total Tax Expense ₹9.3 Cr ₹18.4 Cr ₹10.1 Cr ₹29.46 Cr ₹3.75 Cr ₹58.69 Cr -₹22.3 Cr
Net Profit ₹63.2 Cr ₹19.2 Cr ₹31.6 Cr ₹49.88 Cr ₹78.5 Cr ₹214.48 Cr ₹321.14 Cr
Other Comprehensive Income -₹90 Lakh -₹30 Lakh -₹50 Lakh ₹1.32 Cr ₹2 Lakh -₹1.75 Cr -₹1.88 Cr
Total Comprehensive Income ₹62.3 Cr ₹18.9 Cr ₹31.1 Cr ₹51.2 Cr ₹78.52 Cr ₹212.73 Cr ₹319.26 Cr
EBITDA (computed) ₹51.2 Cr ₹131.7 Cr ₹119.9 Cr ₹141.11 Cr ₹119.09 Cr ₹474.94 Cr ₹544.14 Cr
Basic EPS ₹1.25 ₹1.21 ₹1.99 ₹3.13 ₹4.93 ₹13.47 ₹20.16
Diluted EPS ₹1.25 ₹1.21 ₹1.99 ₹3.13 ₹4.93 ₹13.47 ₹20.16
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,432.7 Cr ₹2,909.6 Cr ₹2,991.9 Cr ₹3,008.47 Cr
Non-current Assets ₹2,381.8 Cr ₹2,425.4 Cr ₹2,451.3 Cr ₹2,429.59 Cr
Current Assets ₹50.9 Cr ₹484.2 Cr ₹540.6 Cr ₹578.88 Cr
Property, Plant & Equipment ₹95.4 Cr ₹514.8 Cr ₹522.6 Cr ₹491.48 Cr
Inventories ₹0 ₹232.4 Cr ₹250.9 Cr ₹313.6 Cr
Trade Receivables ₹23.8 Cr ₹206.3 Cr ₹194.2 Cr ₹188.52 Cr
Cash & Equivalents ₹10.3 Cr ₹12.6 Cr ₹36.1 Cr ₹10.99 Cr
Equity (Net Worth) ₹2,312.3 Cr ₹2,318.1 Cr ₹2,374.5 Cr ₹2,414.55 Cr
Equity Share Capital ₹15.9 Cr ₹15.9 Cr ₹15.9 Cr ₹15.93 Cr
Borrowings (Non-current) ₹50 Cr ₹232.8 Cr ₹246.5 Cr ₹174 Cr
Borrowings (Current) ₹0 ₹73.3 Cr ₹96.4 Cr ₹127.5 Cr
Total Debt (computed) ₹50 Cr ₹306.1 Cr ₹342.9 Cr ₹301.5 Cr
Current Liabilities ₹56.7 Cr ₹310.3 Cr ₹315.4 Cr ₹361.19 Cr
Total Liabilities ₹120.4 Cr ₹591.5 Cr ₹617.4 Cr ₹593.92 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹93.6 Cr ₹135.6 Cr ₹143.2 Cr -₹65.12 Cr -₹6.47 Cr
Investing Cash Flow ₹34 Cr -₹2.3 Cr -₹40.3 Cr ₹31.07 Cr ₹96.02 Cr
Financing Cash Flow -₹129.9 Cr -₹156.8 Cr -₹77.8 Cr ₹22.51 Cr -₹107.37 Cr
Capital Expenditure ₹19.5 Cr ₹21.4 Cr ₹67.6 Cr ₹59.53 Cr ₹1.95 Cr
Free Cash Flow (computed) ₹74.1 Cr ₹114.2 Cr ₹75.6 Cr -₹124.65 Cr -₹8.42 Cr
Dividends Paid ₹79.8 Cr ₹80 Cr ₹80.2 Cr ₹80.06 Cr ₹80.11 Cr
Net Change in Cash -₹2.3 Cr -₹23.5 Cr ₹25.1 Cr -₹11.54 Cr -₹17.82 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹70.3 Cr ₹67.3 Cr ₹66.4 Cr ₹59.5 Cr ₹217.3 Cr ₹196 Cr ₹165.7 Cr ₹166.7 Cr ₹205.8 Cr ₹175.2 Cr ₹186.3 Cr ₹217.4 Cr
Other Income ₹50 Lakh ₹40 Lakh ₹80 Lakh ₹70 Lakh ₹17.9 Cr ₹18.4 Cr ₹43.8 Cr ₹19.5 Cr ₹50.1 Cr ₹19 Cr ₹18.4 Cr ₹15.9 Cr
Total Income ₹70.8 Cr ₹67.7 Cr ₹67.2 Cr ₹60.2 Cr ₹235.2 Cr ₹214.4 Cr ₹209.5 Cr ₹186.2 Cr ₹255.9 Cr ₹194.2 Cr ₹204.7 Cr ₹233.3 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹78 Cr ₹76.8 Cr ₹62.2 Cr ₹65.5 Cr ₹74.1 Cr ₹69.1 Cr ₹94.9 Cr ₹71.9 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹1.5 Cr ₹3.9 Cr ₹1.5 Cr ₹2.6 Cr
Changes in Inventories ₹0 ₹0 ₹0 ₹0 ₹2.7 Cr -₹60 Lakh -₹3.8 Cr -₹5 Cr ₹19.3 Cr -₹1.2 Cr -₹10.3 Cr ₹31.2 Cr
Employee Benefit Expense ₹24.8 Cr ₹29.2 Cr ₹26.6 Cr ₹23.2 Cr ₹50.8 Cr ₹52.1 Cr ₹51.4 Cr ₹48.7 Cr ₹46.5 Cr ₹49.9 Cr ₹46.1 Cr ₹47.5 Cr
Finance Costs ₹90 Lakh ₹90 Lakh ₹2.5 Cr ₹3 Cr ₹7 Cr ₹7.4 Cr ₹7.8 Cr ₹7.6 Cr ₹8.1 Cr ₹8.3 Cr ₹7.1 Cr ₹6.4 Cr
Depreciation & Amortisation ₹1.3 Cr ₹1.6 Cr ₹1.6 Cr ₹1.5 Cr ₹13.4 Cr ₹13.3 Cr ₹13.3 Cr ₹13.1 Cr ₹12.7 Cr ₹12.3 Cr ₹11.9 Cr ₹11.4 Cr
Other Expenses ₹31 Cr ₹25.9 Cr ₹28 Cr ₹26 Cr ₹59.8 Cr ₹56.7 Cr ₹62 Cr ₹56.3 Cr ₹55.2 Cr ₹54.2 Cr ₹53.3 Cr ₹60 Cr
Total Expenses ₹58 Cr ₹57.6 Cr ₹58.7 Cr ₹53.7 Cr ₹211.7 Cr ₹205.7 Cr ₹192.9 Cr ₹186.2 Cr ₹214.4 Cr ₹196.5 Cr ₹204.5 Cr ₹231 Cr
Profit Before Exceptional Items & Tax ₹12.8 Cr ₹10.1 Cr ₹8.5 Cr ₹6.5 Cr ₹23.5 Cr ₹8.7 Cr ₹16.6 Cr ₹0 ₹41.5 Cr -₹2.3 Cr ₹20 Lakh ₹2.3 Cr
Exceptional Items -₹8.7 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹11.2 Cr ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹4.1 Cr ₹10.1 Cr ₹8.5 Cr ₹6.5 Cr ₹23.5 Cr ₹8.7 Cr ₹16.6 Cr -₹11.2 Cr ₹41.5 Cr -₹2.3 Cr ₹20 Lakh ₹2.3 Cr
Total Tax Expense -₹53.1 Cr ₹3.5 Cr ₹56.5 Cr ₹2.4 Cr ₹9.9 Cr ₹3.4 Cr ₹6.1 Cr -₹1 Cr ₹9 Cr ₹10 Lakh ₹60 Lakh ₹40 Lakh
Net Profit ₹57.2 Cr ₹6.6 Cr -₹6.4 Cr ₹5.8 Cr ₹13.6 Cr ₹5.3 Cr ₹10.5 Cr -₹10.2 Cr ₹32.5 Cr -₹2.4 Cr -₹40 Lakh ₹1.9 Cr
Other Comprehensive Income -₹10 Lakh ₹10 Lakh -₹80 Lakh -₹10 Lakh ₹30 Lakh -₹20 Lakh -₹20 Lakh -₹20 Lakh ₹10 Lakh -₹20 Lakh -₹20 Lakh -₹20 Lakh
Total Comprehensive Income ₹57.1 Cr ₹6.7 Cr -₹7.2 Cr ₹5.7 Cr ₹13.9 Cr ₹5.1 Cr ₹10.3 Cr -₹10.4 Cr ₹32.6 Cr -₹2.6 Cr -₹60 Lakh ₹1.7 Cr
EBITDA (computed) ₹15 Cr ₹12.6 Cr ₹12.6 Cr ₹11 Cr ₹43.9 Cr ₹29.4 Cr ₹37.7 Cr ₹20.7 Cr ₹62.3 Cr ₹18.3 Cr ₹19.2 Cr ₹20.1 Cr
Basic EPS ₹3.59 ₹0.42 ₹-3.02 ₹0.26 ₹0.86 ₹0.33 ₹0.66 ₹-0.64 ₹2.05 ₹-0.15 ₹-0.03 ₹0.12
Diluted EPS ₹3.59 ₹0.42 ₹-3.02 ₹0.26 ₹0.86 ₹0.33 ₹0.66 ₹-0.64 ₹2.05 ₹-0.15 ₹-0.03 ₹0.12
Latest 12 quarters shown of 25 on record.
Segment · FY 2021 (annual) Revenue Result (PBIT) Assets Liabilities
Life Science Ingredients ₹2,709.5 Cr ₹381.5 Cr - -
Pharmaceuticals ₹0 ₹0 - -
Want more history and ratios?
You're viewing the latest exchange-filed financials for Jubilant Pharmova Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Jubilant Pharmova Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 47.68%, foreign institutional investors hold 15.90%, domestic institutional investors hold 11.62%, retail and other public shareholders hold 24.24% of Jubilant Pharmova Limited. The company had 86,347 shareholders on record.

Promoters: 47.68%DII (Domestic Institutional): 11.62%FII (Foreign Institutional): 15.90%Retail & Others: 24.24%Others: 0.56%
Mar 2026
QUARTER
47.68% Promoters
11.62% DII (Domestic Institutional)
15.90% FII (Foreign Institutional)
24.24% Retail & Others
0.56% Others
Promoter holding - history
Now 47.68% · Mar 2026High 54.02% · Dec 2015Low 47.68% · Jun 2025
46%48.5%51%53.5%56%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 54.02%Mar 2016: 54.02%Jun 2016: 54.02%Sep 2016: 54.02%Dec 2016: 54.02%Mar 2017: 54.02%Jun 2017: 54.02%Sep 2017: 54.02%Dec 2017: 54.02%Mar 2018: 50.68%Jun 2018: 50.68%Sep 2018: 50.68%Dec 2018: 50.68%Mar 2019: 50.68%Jun 2019: 50.68%Sep 2019: 50.68%Dec 2019: 50.68%Mar 2020: 50.68%Jun 2020: 50.68%Sep 2020: 50.68%Dec 2020: 50.68%Mar 2021: 50.68%Jun 2021: 50.68%Sep 2021: 50.68%Dec 2021: 50.68%Mar 2022: 50.68%Jun 2022: 50.68%Sep 2022: 50.68%Dec 2022: 50.68%Mar 2023: 50.68%Jun 2023: 50.68%Sep 2023: 50.68%Dec 2023: 50.68%Mar 2024: 50.68%Jun 2024: 50.68%Sep 2024: 50.68%Dec 2024: 50.68%Mar 2025: 50.68%Jun 2025: 47.68%Sep 2025: 47.68%Dec 2025: 47.68%Mar 2026: 47.68%54.02%47.68%47.68%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters47.68%47.68%47.68%47.68%50.68%50.68%
Public51.76%51.75%51.69%51.77%48.77%48.77%
Employee Trusts0.56%0.57%0.63%0.56%0.56%0.56%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters47.68%50.68%50.68%50.68%50.68%50.68%50.68%50.68%50.68%54.02%54.02%
Public51.76%48.77%48.74%49.19%49.26%49.26%49.32%49.32%47.12%43.75%43.52%
Employee Trusts0.56%0.56%0.58%0.13%0.07%0.07%0.00%0.01%2.20%2.23%2.45%
Promoter change (YoY, %pts)-3.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00-3.34+0.00-

Board & Governance of Jubilant Pharmova Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Jubilant Pharmova Limited has 10 directors - 6 independent and 2 executive. The board is chaired by Shyam Sunder Bhartia.

DirectorPositionOn board sinceListed boards
Shyam Sunder Bhartia Non-Executive - Non Independent Director · Chairperson 1978-06-21 4
Hari Shanker Bhartia Non-Executive - Non Independent Director 1983-11-01 6
Sushil Kumar Roongta Non-Executive - Independent Director 2017-05-23 6
Vivek Mehra Non-Executive - Independent Director 2017-05-23 6
Arun Seth Non-Executive - Independent Director 2018-10-22 4
Shirish Gundopant Belapure Non-Executive - Independent Director 2023-03-07 4
Priyavrat Bhartia Executive Director · MD 2017-05-23 6
Arjun Shanker Bhartia Executive Director · MD 2017-05-23 3
Shivpriya Nanda Non-Executive - Independent Director 2024-04-01 2
Harsh Mahajan Non-Executive - Independent Director 2024-04-01 1
Board Committees
CommitteeMembers
Audit Committee Vivek Mehra (Chairperson), Sushil Kumar Roongta, Arun Seth, Shivpriya Nanda
Nomination and remuneration committee Sushil Kumar Roongta (Chairperson), Shyam Sunder Bhartia, Vivek Mehra, Arun Seth
Stakeholders Relationship Committee Arun Seth (Chairperson), Priyavrat Bhartia, Harsh Mahajan, Shivpriya Nanda
Risk Management Committee Sushil Kumar Roongta (Chairperson), Arun Seth, Shirish Gundopant Belapure, Priyavrat Bhartia, Arjun Shanker Bhartia, Vivek Mehra, Shivpriya Nanda, Harsh Mahajan
Corporate Social Responsibility Committee Shivpriya Nanda (Chairperson), Sushil Kumar Roongta, Priyavrat Bhartia, Arjun Shanker Bhartia, Shirish Gundopant Belapure, Arun Seth, Harsh Mahajan

Group Structure of Jubilant Pharmova Limited

Jubilant Pharmova Limited has 7 subsidiary companies. This group structure data is as of FY 2022. The corporate group structure reflects Jubilant Pharmova Limited's business expansion strategy and organizational complexity.

7
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Jubilant Generics Limited U24100UP2013FLC060821 -
Jubilant Biosys Limited U24110UP1998PLC029591 -
Jubilant Clinsys Limited U24232UP2004PLC029008 -
Jubilant First Trust Healthcare Limited U74110UP2006PLC035993 -
Jubilant Draximage Limited U74900UP2009FLC038194 -
Jubilant Therapeutics India Limited U74994UP2019PLC114901 -

Showing major subsidiaries. Total: 7.

Charges & Borrowings of Jubilant Pharmova Limited

Open charges
₹360 Cr
Satisfied charges
₹9,185.57 Cr
Breakdown by lending institutions
Others₹210.00 Cr
Hdfc Bank Limited₹100.00 Cr
Yes Bank Limited₹50.00 Cr
Latest charge details
DateLenderAmountStatus
29 Aug 2025 Others ₹50 Cr Open
26 Feb 2024 Hdfc Bank Limited ₹100 Cr Open
28 Aug 2023 Others ₹100 Cr Open
23 Mar 2023 Yes Bank Limited ₹50 Cr Open
15 Feb 2023 Others ₹60 Cr Open

Total charge records: 84 View all charges

Employees and EPFO Compliance at Jubilant Pharmova Limited

Jubilant Pharmova Limited has a workforce of 1,055 employees as of Mar 30, 2024.

Employee count
1,055
Active EPFO establishments
8
Employee growth
2.73%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Jubilant Pharmova Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Jubilant Pharmova Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Jubilant Pharmova Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Jubilant Pharmova Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Jubilant Pharmova Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Jubilant Pharmova Limited

MSME Payment Delays by Jubilant Pharmova Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Jubilant Pharmova Limited

Subsidiaries & Group Companies of Jubilant Pharmova Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Jubilant Pharmova Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Jubilant Pharmova Limited

MCA Filings & Documents of Jubilant Pharmova Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Jubilant Pharmova Limited

Charges
14 Nov 2025
A charge registered on 25 Jul 2022 via Charge ID 100600986 with Axis Bank Limited was fully satisfied on 14 Nov 2025.
Charges
28 Oct 2025
A charge registered on 20 Sep 2022 via Charge ID 100616639 with Others was fully satisfied on 28 Oct 2025.
Charges
13 Oct 2025
A charge with Others of Rs. 50.00 Cr registered on 29 Aug 2025 with Charge ID 101158066 was modified on 13 Oct 2025.
Directors
01 Oct 2025
Arun Kumar Sharma was appointed as a CFO on 01 Oct 2025 & has been associated with this company since 9 months 8 days.
Charges
29 Aug 2025
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101158066 was registered on 29 Aug 2025.
Activity
29 Aug 2025
Jubilant Pharmova Limited last Annual general meeting of members was held on 29 Aug 2025 as per latest MCA records.

Recent News on Jubilant Pharmova Limited

Frequently Asked Questions about Jubilant Pharmova Limited

Jubilant Pharmova Limited is an active public limited company in the pharma sector based in U P, Uttar Pradesh, India. It was incorporated on 21 June 1978 (48+ years old) and is registered under CIN L24116UP1978PLC004624. Listed on BSE: 530019 and NSE: JUBLPHARMA. The company has 1,055 employees.

Jubilant Pharmova Limited reported revenue of ₹7,291.3 Cr for FY 2025 (up 8.00% YoY).

The current directors of Jubilant Pharmova Limited are:

The primary industry of Jubilant Pharmova Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Jubilant Pharmova Limited is listed on both BSE (code: 530019) and NSE (symbol: JUBLPHARMA).

Jubilant Pharmova Limited can be reached at the registered office: Bhartiagram Gajraulajyotiba Phoolay Nagar, U P, Uttar Pradesh, India – 244223, or through the website jubilantpharmova.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available